

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum

Dimitrios Boumpas

Gerd Burmester

Mary Crow

Iain McInnes

Thomas Pap

David Pisetsky

Désirée van der Heijde

Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

T: +44 (0)20 7383 6250

F: +44 (0)20 7383 6668

E: [ard@bmj.com](mailto:ard@bmj.com)

Twitter: @ARD\_BMJ

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Impact Factor: 12.811

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2017 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 1953** Classification and diagnostic criteria in Sjögren's syndrome: a long-standing and still open controversy  
*C Vitali, N Del Papa*

**Criteria**

- 1955** 2017 European League Against Rheumatism/ American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups  
*I E Lundberg, A Tjårlund, M Bottai, V P Werth, C Pilkington, M de Visser, L Alfredsson, A A Amato, R J Barohn, M H Liang, J A Singh, R Aggarwal, S Arndt, H Chinoy, R G Cooper, K Dankó, M M Dimachie, B M Feldman, I Garcia-De La Torre, P Gordon, T Hayashi, J D Katz, H Kohsaka, P A Lachenbruch, B A Lang, Y Li, C V Oddis, M Olesinska, A M Reed, L Rutkowska-Sak, H Sanner, A Selva-O'Callaghan, Y-W Song, J Vencovsky, S R Ytterberg, F W Miller, L G Rider, The International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland)*

**Recommendations**

- 1965** European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative  
*N Groot, N de Graeff, S D Marks, P Brogan, T Avcin, B Bader-Meuier, P Dolezalova, B M Feldman, I Kone-Paut, P Lahdenne, L McCann, S Özen, C A Pilkington, A Ravelli, A van Royen-Kerkhof, Y Uziel, B J Vastert, N M Wulffraat, M W Beresford, S Kamphuis*
- 1974** The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology  
*I Möller, I Janta, M Backhaus, S Ohrndorf, D A Bong, C Martinoli, E Filippucci, L M Sconfienza, L Terslev, N Damjanov, H B Hammer, I Sudol-Szopinska, W Grassi, P Balint, G A W Bruyn, M A D'Agostino, D Hollander, H J Siddle, G Supp, W A Schmidt, A Iagnocco, J Koski, D Kane, D Fodor, A Bruns, P Mandl, G S Kaeley, M Micu, C Ho, V Vlad, M Chávez-López, G Filippou, C E Cerón, R Nestorova, M Quintero, R Wakefield, L Carmona, E Naredo*

**Clinical and epidemiological research**

- 1980** Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients  
*H Tsuboi, S Hagiwara, H Asashima, H Takahashi, T Hirota, H Noma, H Umehara, A Kawakami, H Nakamura, H Sano, K Tsubota, Y Ogawa, E Takamura, I Saito, H Inoue, S Nakamura, M Moriyama, T Takeuchi, Y Tanaka, S Hirata, T Mimori, I Matsumoto, T Sumida*

- 1986** Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4  
*P Emery, J Vencovsky, A Sylwestrzak, P Leszczynski, W Porawska, B Stasiuk, J Hilt, Z Mosterova, S Y Cheong, J Ghil*

- 1992** Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece  
*I Gergianaki, A Fanourakis, A Repa, M Tzanakakis, C Adamichou, A Pompieri, G Spirou, A Bertias, E Kabouraki, I Tzanakis, L Chatzi, P Sidropoulos, D T Boumpas, G K Bertias*

- 2001** Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study  
*T Takeuchi, C Thorne, G Karpouzias, S Sheng, W Xu, R Rao, K Fei, B Hsu, P P Tak*

- 2009** Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016  
*M G Tektonidou, L B Lewandowski, J Hu, A Dasgupta, M M Ward*

- 2017** Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis  
*Å Mantel, M Holmqvist, T Jernberg, S Wällberg-Jonsson, J Askeling*

- 2025** Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project  
*L K Mercer, A C Regierer, X Mariette, W G Dixon, E Baecklund, K Hellgren, L Dreyer, M L Hetland, R Cordtz, K Hyrich, A Strangfeld, A Zink, H Canhao, M V Hernandez, F Tubach, J-E Gottenberg, J Morel, J Zavada, F Iannone, J Askeling, J Listing*

**MORE CONTENTS ►**

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme.

<http://authors.bmj.com/open-access/>



Member since 2008  
JN00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 2031** Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis  
*M K Jonsson, N P Sundlister, H H Nordal, H B Hammer, A-B Aga, I C Olsen, K A Brokstad, D van der Heijde, T K Kvien, B-T S Fevang, S Lillegraven, E A Haavardsholm*
- 2038** The effects of structural damage on functional disability in psoriatic arthritis  
*A Kerschbaumer, D Baker, J S Smolen, D Aletaha*
- 2046** Genome-wide association and functional studies identify a role for matrix Gla protein in osteoarthritis of the hand  
*W den Hollander, C G Boer, D J Hart, M S Yau, Y F M Ramos, S Mestrusty, L Broer, J Deelen, L A Cupples, F Rivadeneira, M Kloppenburg, M Peters, T D Spector, A Hofman, P E Slagboom, R G H H Nelissen, A G Uitterlinden, D T Felson, A M Valdes, I Meulenbelt, J J B van Meurs*
- 2054** Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort  
*C Gaujoux-Viala, N Rincheval, M Dougados, B Combe, B Fautrel*
- 2061** Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series  
*S T Kim, J Tayar, V A Trinh, M Suarez-Almazor, S Garcia, P Hwu, D H Johnson, M Uemura, A Diab*
- 2065** Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study  
*L K Stamp, P T Chapman, M Barclay, A Home, C Frampton, P Tan, J Drake, N Dalbeth*
- 2071** Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)  
*M F Ugarte-Gil, D Wojdyla, G J Pons-Estel, L J Catoggio, C Drenkard, J Sarano, G A Berbotto, E F Borba, E I Sato, J C Tavares Brenol, O Uribe, L A Ramirez Gómez, M Guibert-Toledano, L Massardo, M H Cardiel, L H Silveira, R Chacón-Díaz, G S Alarcón, B A Pons-Estel, on behalf of GLADEL*

## Basic and translational research

- 2075** Chemotaxis of V $\delta$ 2 T cells to the joints contributes to the pathogenesis of rheumatoid arthritis  
*W-X Mo, S-S Yin, H Chen, C Zhou, J-X Zhou, L-D Zhao, Y-Y Fei, H-X Yang, J-B Guo, Y-J Mao, L-F Huang, W-J Zheng, W Zhang, J-M Zhang, W He, X Zhang*
- 2085** A novel Pysin-Associated Autoinflammation with Neutrophilic Dermatitis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever  
*F Moghaddas, R Llamas, D De Nardo, H Martinez-Banacochoa, J J Martinez-Garcia, P Mesa-del-Castillo, P J Baker, V Gargallo, A Mensa-Vilaro, S Canna, I P Wicks, P Pelegrin, J I Arostegui, S L Masters*

- 2095** B cell OX40L supports T follicular helper cell development and contributes to SLE pathogenesis  
*A Cortini, U Ellinghaus, T H Malik, D S Cunningham-Graham, M Botto, T J Vyse*

- 2105** Identification of a transitional fibroblast function in very early rheumatoid arthritis  
*A Filer, L S C Ward, S Kemble, C S Davies, H Munir, R Rogers, K Raza, C D Buckley, G B Nash, H M McGettrick*

## Correction

- 2103** Erratum: *Dietary intake of fibre and risk of knee osteoarthritis in two US prospective cohorts*

## Electronic pages

### Correspondence

- e49** Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis  
*L Piriälä, T Sokka, M J Kauppi, V M Rantalaiho, E Mervaala, K Puolakka*
- e50** Response to: 'The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis' by Piriälä *et al*  
*J S Smolen, R B M Landewé, D van der Heijde*
- e51** HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study  
*J Bluett, S-A Owen, J Massey, A Alfirevic, M Pirmohamed, D Plant, S M M Verstappen, A Barton, on behalf of The Pneumonitis Study Consortium*
- e52** Response to: 'HLA-A\* 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome wide association study' by Bluett *et al*  
*H Furukawa, S Oka, K Shimada, N Tsuchiya, S Tohma, on behalf of the Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) Study Consortium*
- e53** EULAR recommendations underplay importance of severe anxiety and depression in fibromyalgia treatment  
*C Mercieca, A A Borg*
- e54** EULAR recommendations for management of fibromyalgia  
*G J Macfarlane, C Kronisch, F Atzeni, W Häuser, E H Choy, K Amris, J Branco, F Dincer, P Leino-Arjas, K Longley, G McCarthy, S Makri, S Perrot, P Sarzi Puttini, A Taylor, G T Jones*